Actively Recruiting
Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion
Led by Shanghai East Hospital · Updated on 2026-01-21
652
Participants Needed
1
Research Sites
184 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A prospective, multicenter, open-label, randomized controlled study to assess the effects of early intensive lipid-lowering initiated before endovascular treatment setting on (i) functional outcome in patients with acute ischemic stroke between preoperative intensive lipid-lowering therapy with PCSK9 inhibitor (PCSK9i) and guideline-recommended standard of care (SoC)(ii) safety in these patients.
CONDITIONS
Official Title
Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Diagnosed with acute ischemic stroke involving large vessel blockage in the anterior brain circulation
- Planned to have endovascular intervention within 24 hours of symptom onset or last known well time
- Able to provide informed consent or have a legal representative provide consent
You will not qualify if you...
- ASPECTS score 5 or less on cranial CT scan
- Pre-existing disability with a modified Rankin Scale score greater than 2
- Allergy to PCSK9 inhibitors
- Received PCSK9 monoclonal antibody within 1 month or PCSK9 siRNA therapy within 6 months before enrollment
- Severe kidney failure with eGFR below 15 mL/min/1.73m2
- Active liver disease or liver enzyme levels more than three times the normal limit
- Severe non-cardiovascular illness expected to limit life expectancy to under 3 months
- Pregnant or breastfeeding women
- Participation in other clinical trials
- Any other conditions the investigator considers unsuitable for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai East Hospital, Tongji University
Shanghai, China, 200127
Actively Recruiting
Research Team
G
Gang Li, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here